4.5 Article

MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1a expression in third-sphere forming breast cancer stem cell-like cells

期刊

CANCER SCIENCE
卷 103, 期 6, 页码 1058-1064

出版社

WILEY
DOI: 10.1111/j.1349-7006.2012.02281.x

关键词

-

类别

资金

  1. National Natural Science Foundation of China [NSFC 81072147, NSFC 31171336]
  2. Natural Science Foundation of Chongqing Science & Technology Commission, China

向作者/读者索取更多资源

Cancer stem cells (CSCs) are predicted to be critical drivers of tumor progression due to their stemness, but the molecular mechanism of CSCs in regulating metastasis remains to be elucidated. Epithelial-mesenchymal transition (EMT), hypoxia-inducible factor (HIF)-1a, and miR-21, all of which contribute to cell migration for metastasis, are interrelated with CSCs. In the present study, third-sphere forming (3-S) CSC-like cells, which showed elevated CSC surface markers (ALDH1+ and CD44+/CD24-/low) and sphereforming capacity as well as migration and invasion capacities, were cultured and isolated from breast cancer MCF-7 parental cells, to evaluate the role of miR-21 in regulating the CSC-like cell biological features, especially EMT. EMT, which was assessed by overexpression of mesenchymal cell markers (N-cadherin, Vimentin, alpha-smooth muscle actin [a-SMA]) and suppression of epithelial cell marker (E-cadherin), was induced in 3-S CSC-like cells. Moreover, both of HIF-1a and miR-21 were upregulated in the CSC-like cells. Interestingly, antagonism of miR-21 by antagomir led to reversal of EMT, downexpression of HIF-1a, as well as suppression of invasion and migration, which indicates a key role of miR-21 involved in regulate CSC-associated features. In conclusion, we demonstrated that the formation of CSC-like cells undergoing process of EMT-like associated with overexpression of HIF-1a, both of which are regulated by miR-21. (Cancer Sci 2012; 103: 10581064)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据